Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
CMS is also considering an alternative policy whereby CMS would calculate the benchmark period manufacturer price for a new NDC-9 of an existing Part D rebatable drug that lacks AMP data for the time period described in 428.202(c)(1) or (2) using a reasonable proxy metric
But these are at very low levels or under strict safety regulations
Duplicative Services and Concurrent Billing Restrictions In this section, we identify the services that would overlap substantially with APCM services based on the proposed elements of the scope of service for APCM which we have built into the service descriptors for GPCM1, GPCM2, and GPCM3 (see sections II.G.2.b
In addition, a wide array of interested parties recommended that CMS create a mechanism through which covered entities would retrospectively submit data to CMS identifying 340B claims dispensed under Part D
The key difference lies in the presence of dependence and severity of symptoms
US$ 23.42
US$ 23.06
:max_bytes(150000):strip_icc()/GettyImages-835241778-ffb0b1255cd6444ca89314ac7732235d.jpg)
US$ 21.18
